Provider of diagnostic services for early detection of Alzheimer's disease. The company is developing diagnostic tests by using next-generation sequencing analysis for the detection of biomarkers β-amyloid nor tau. The test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA. The company was founded in 2017 and headquartered in Barcelona, Spain. It has raised $12.9M in series a funding, with backing from EIT Health, Alzheimer's Drug Discovery, Europa, Lavanda, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Neurology, Life Sciences - Clinical Genomics space.
← All startups
ADmit Therapeutics
Series AProvider of diagnostic services for early detection of Alzheimer's disease. The company is developing diagnostic tests by using next-generation sequencing analysis for the detection of biomarkers β-amyloid nor tau. The test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA. The company was founded in 2017 and headquartered in Barcelona, Spain. It…
About
Business model
Neurology > In-Vitro Diagnostics > Neurodegenerative > Alzheimer Disease,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Epigenomics
Institutional investors
EIT HealthAlzheimer's Drug DiscoveryEuropaLavandaShip2B VenturesWA4STEAMClaveBstartup Banco SabadellShip2BEuropean Investment FundGENESIS BiomedCapital CellCatalonia Trade & InvestmentAdditio VenturesEIC Fund
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.